Free Trial
NASDAQ:BDSX

Biodesix Q1 2025 Earnings Report

Biodesix logo
$0.52 -0.01 (-1.52%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$0.53 +0.01 (+2.32%)
As of 05/2/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biodesix EPS Results

Actual EPS
N/A
Consensus EPS
-$0.08
Beat/Miss
N/A
One Year Ago EPS
N/A

Biodesix Revenue Results

Actual Revenue
N/A
Expected Revenue
$19.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biodesix Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Biodesix Earnings Headlines

Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
Scotiabank Keeps Their Buy Rating on Biodesix (BDSX)
See More Biodesix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biodesix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biodesix and other key companies, straight to your email.

About Biodesix

Biodesix (NASDAQ:BDSX) operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

View Biodesix Profile

More Earnings Resources from MarketBeat